13F filer · CIK 1697748 ↗
ARK Invest
You are looking at Q4 2019. See the latest, Q2 2026 →
Reported value
$3.96B
−13% on the quarter before
Positions
218
18 new · 24 sold out
Top 10
45.2%
of the value
Est. gain
−$442.1M
on stocks held all quarter
Est. return
−11.7%
on those stocks since Q3 2019
Positions as of Dec 31, 2019, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.
Portfolio at a glance
- New
- Added
- Cut
- Same
- Options
Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2019. Striped tiles are options.
Largest buys
Since Q3 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Zillow Group Inc~$110.1MNew · 0.0% → 2.8%+2,407,049 shares
- Roku Inc~$60.0MAdded · 0.6% → 2.5%+448,310 shares
- Twitter Inc~$46.5MAdded · 1.3% → 2.4%+1,451,656 shares
- Invitae Corp~$43.0MAdded · 3.3% → 4.3%+2,667,936 shares
- MercadoLibre~$36.9MAdded · 0.5% → 1.5%+64,520 shares
- The Trade Desk~$33.1MAdded · 0.6% → 1.8%+127,607 shares
- Pinterest Inc~$28.6MAdded · 0.1% → 0.8%+1,534,055 shares
- Xilinx Inc~$25.0MAdded · 1.7% → 2.6%+256,211 shares
- Block~$20.3MAdded · 4.6% → 5.9%+323,893 shares
- Lendingtree Inc~$19.2MAdded · 1.5% → 2.2%+63,188 shares
Largest sells
Since Q3 2019, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.
- Tesla~$188.5MCut · 6.2% → 7.6%−450,622 shares
- Zillow Group Inc~$69.7MSold out · 1.5% → 0.0%−2,336,106 shares
- Nvidia~$69.6MCut · 2.0% → 1.4%−295,770 shares
- Aptiv Plc~$29.2MCut · 0.8% → 0.2%−307,685 shares
- Teradyne~$20.5MCut · 1.2% → 1.1%−300,694 shares
- Teladoc Health Inc~$17.5MCut · 1.4% → 1.6%−209,431 shares
- Bristol-Myers Squibb Co~$17.2MCut · 0.4% → 0.1%−267,658 shares
- Regeneron Pharmaceuticals Inc~$14.8MCut · 0.2% → 0.0%−39,984 shares
- Editas Medicine Inc~$14.4MCut · 2.4% → 3.3%−485,121 shares
- Nanostring Technologies Inc~$8.3MCut · 1.6% → 2.1%−296,853 shares
Holdings
As of Dec 31, 2019. Changes are in shares against Sep 30, 2019, so a price move alone never reads as a buy or a sale.
| Holding | Value | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TeslaCommon Stock · shares −38% · price +73.7% | 7.6% | $302.0M | +$128.1M | ||||||||
| Illumina IncCommon Stock · shares +4.7% · price +9.0% | 6.1% | $241.4M | +$19.1M | ||||||||
| BlockCommon Stock · shares +9.5% · price +1.0% | 5.9% | $234.5M | +$2.1M | ||||||||
| Crispr Therapeutics AgCommon Stock · shares +6.3% · price +48.6% | 4.5% | $180.1M | +$55.4M | ||||||||
| Stratasys LtdCommon Stock · shares +8.5% · price −5.1% | 4.3% | $171.2M | −$8.4M | ||||||||
| Invitae CorpCommon Stock · shares +34% · price −16.3% | 4.3% | $169.5M | −$24.6M | ||||||||
| Editas Medicine IncCommon Stock · shares −9.8% · price +30.2% | 3.3% | $131.7M | +$30.6M | ||||||||
| Intellia Therapeutics IncCommon Stock · shares +3.2% · price +9.9% | 3.2% | $128.2M | +$11.2M | ||||||||
| 2u IncCommon Stock · shares +2.9% · price +47.4% | 3.2% | $125.2M | +$39.1M | ||||||||
| Zillow Group IncCommon Stock · shares New | 2.8% | $110.1M | — | ||||||||
| Xilinx IncCommon Stock · shares +32% · price +2.0% | 2.6% | $104.3M | +$1.5M | ||||||||
| Roku IncCommon Stock · shares +155% · price +31.6% | 2.5% | $98.8M | +$9.3M | ||||||||
| Splunk IncCommon Stock · shares −5.2% · price +27.1% | 2.4% | $94.7M | +$20.2M | ||||||||
| Twitter IncCommon Stock · shares +97% · price −22.2% | 2.4% | $94.5M | −$13.7M | ||||||||
| Lendingtree IncCommon Stock · shares +29% · price −2.3% | 2.2% | $86.4M | −$1.5M | ||||||||
| Nanostring Technologies IncCommon Stock · shares −8.9% · price +28.9% | 2.1% | $85.0M | +$19.0M | ||||||||
| Proto Labs IncCommon Stock · shares +18% · price −0.5% | 2.1% | $81.7M | −$374,254 | ||||||||
| Veracyte IncCommon Stock · shares +8.0% · price +16.3% | 2.0% | $77.9M | +$10.1M | ||||||||
| SalesforceCommon Stock · shares +18% · price +9.6% | 1.9% | $76.5M | +$5.7M | ||||||||
| The Trade DeskCommon Stock · shares +89% · price +38.5% | 1.8% | $70.4M | +$10.4M | ||||||||
| Teladoc Health IncCommon Stock · shares −22% · price +23.6% | 1.6% | $62.8M | +$12.0M | ||||||||
| MercadoLibreCommon Stock · shares +170% · price +3.8% | 1.5% | $58.6M | +$784,674 | ||||||||
| Tencent Holdings LtdADR · shares −1.1% · price +15.3% | 1.4% | $56.4M | +$7.5M | ||||||||
| NvidiaCommon Stock · shares −56% · price +35.2% | 1.4% | $55.2M | +$14.4M | ||||||||
| NetflixCommon Stock · shares +18% · price +20.9% | 1.4% | $53.8M | +$7.9M | ||||||||
| Total · 218 positions | 100% | $3.96B | −$442.1M |
Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.
What made money
From Q3 2019 to Q4 2019: 199 stocks held throughout, down $442.1M (−11.7%).
- Tesla+$128.1M+74%
- Crispr Therapeutics Ag+$55.4M+49%
- 2u Inc+$39.1M+47%
- Editas Medicine Inc+$30.6M+30%
- Splunk Inc+$20.2M+27%
- Matrix It Ltd−$121.5M−100%
- Fattal Holdings 1998 Ltd−$123.0M−100%
- One Software Technologies Ltd−$128.3M−100%
- Fms Enterprises Migun Ltd−$130.1M−100%
- Partner Communications Co Ltd−$134.3M−100%
Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out, 1 split read into the share counts.
Reported value by quarter
The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.
Every quarter's filing
| Quarter | Reported value | Filing | |
|---|---|---|---|
| Q2 2026 | Aug 14, 2026 | $15.40B+20% | SEC ↗ |
| Q1 2026 | May 12, 2026 | $12.86B−15% | SEC ↗ |
| Q4 2025 | Feb 11, 2026 | $15.07B−10% | SEC ↗ |
| Q3 2025 | Nov 12, 2025 | $16.80B+23% | SEC ↗ |
| Q2 2025 | Jul 30, 2025 | $13.64B+37% | SEC ↗ |
| Q1 2025 | May 7, 2025 | $9.99B−17% | SEC ↗ |
| Q4 2024 | Feb 4, 2025 | $12.01B+10% | SEC ↗ |
| Q3 2024 | Oct 31, 2024 | $10.93B−3% | SEC ↗ |
| Q2 2024 | Jul 26, 2024 | $11.27B−22% | SEC ↗ |
| Q1 2024 | Apr 18, 2024 | $14.44B−14% | SEC ↗ |
| Q4 2023 | Jan 17, 2024 | $16.89B+29% | SEC ↗ |
| Q3 2023 | Oct 18, 2023 | $13.07B−13% | SEC ↗ |
| Q2 2023 | Jul 10, 2023 | $15.10B+4% | SEC ↗ |
| Q1 2023 | Apr 17, 2023 | $14.55B+26% | SEC ↗ |
| Q4 2022 | Jan 24, 2023 | $11.54B−20% | SEC ↗ |
| Q3 2022 | Oct 17, 2022 | $14.35B−15% | SEC ↗ |
| Q2 2022 | Jul 11, 2022 | $16.91B−29% | SEC ↗ |
| Q1 2022 | Apr 18, 2022 | $23.96B−28% | SEC ↗ |
| Q4 2021 | Jan 28, 2022 | $33.08B−21% | SEC ↗ |
| Q3 2021 | Nov 12, 2021 | $41.64B−23% | SEC ↗ |
| Q2 2021 | Aug 5, 2021 | $53.74B+7% | SEC ↗ |
| Q1 2021 | May 13, 2021 | $50.34B+34% | SEC ↗ |
| Q4 2020 | Feb 12, 2021 | $37.59B+123% | SEC ↗ |
| Q3 2020 | Oct 30, 2020 | $16.86B+81% | SEC ↗ |
| Q2 2020 | Aug 11, 2020 | $9.30B+132% | SEC ↗ |
| Q1 2020 | May 14, 2020 | $4.01B+1% | SEC ↗ |
| Q4 2019 | Jan 31, 2020 | $3.96B−13% | SEC ↗ |
| Q3 2019 | Nov 12, 2019 | $4.58B+15% | SEC ↗ |
| Q2 2019 | Jul 30, 2019 | $3.97B+13% | SEC ↗ |
| Q1 2019 | May 13, 2019 | $3.50B+42% | SEC ↗ |
| Q4 2018 | Feb 11, 2019 (amended) | $2.46B−26% | SEC ↗ |
| Q3 2018 | Nov 7, 2018 | $3.31B+21% | SEC ↗ |
| Q2 2018 | Aug 7, 2018 | $2.73B+36% | SEC ↗ |
| Q1 2018 | May 14, 2018 | $2.01B+60% | SEC ↗ |
| Q4 2017 | Feb 12, 2018 | $1.26B+53% | SEC ↗ |
| Q3 2017 | Nov 9, 2017 | $819.3M+60% | SEC ↗ |
| Q2 2017 | Aug 11, 2017 | $513.6M+48% | SEC ↗ |
| Q1 2017 | May 15, 2017 | $346.9M+26% | SEC ↗ |
| Q4 2016 | Feb 13, 2017 | $274.9M | SEC ↗ |